ArticleDiscover oncology2025
Cell cycle-related biomarker lineage promotes the malignant progression of recurrent IDH wild-type glioma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundGlioma is the most common primary brain tumor in adults, malignant progression and recurrence are inevitable. Although mechanisms of glioma development and progression have been demonstrated, the underlying driver pathway activation and the related therapeutic targets of recurrent gliomas, notably recurrent isocitrate dehydrogenase (IDH) wild-type gliomas, are rudimentary.
methodsWe analyzed the differential expression genes (DEGs) between two subgroups of 80 IDH wild-type recurrent gliomas from the Chinese Glioma Genome Atlas (CGGA). We then constructed and validated an 11-gene signature based on cell cycle-related DEGs. SPSS and R languages were used for statistical analysis and graphical work.
resultsWe proposed a molecular classification based on gene expression profiles and divided them into two subtypes that differed in their biological features and prognoses. We then constructed and validated an 11-gene signature based on cell cycle-related DEGs to better explore the association between cell cycle and tumor malignant progression. Additionally, the risk score could predict the sensitivity of patients to radiotherapy or chemotherapy. Functional analysis demonstrated that genes associated with the high-risk group were involved in various aspects of glioma cell cycle regulation. Moreover, the knockdown of SYCE2 blocked cell proliferation and improved cell sensitivity to temozolomide (TMZ).
conclusionThis study developed a cell cycle-related signature for predicting the prognosis of recurrent IDH wild-type glioma, and identified a novel biomarker SYCE2, which could be used to assess the response of patients to TMZ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.